Nucynta ER (Tapentadol HCl) Patent Expiration, LOE Window & CMS Spending

Nucynta ER (Tapentadol HCl) by Collegium: FDA Orange Book LOE 2029-03-22, 2 AB generics, $55.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCollegium
FDA Application & PathwayN200533 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-03-22
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$55.2M
2024 Medicare Part D Spend$47.7M
2024 Medicaid Spend$7.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel